Superworth

Nektar Therapeutics price to book ratio NKTR

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
1.4×
10-year median
3.0×
Against its 10-year history
18th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.4× to 199×
Peer median
2.4×

Nektar Therapeutics' price to book ratio is 1.4× as of Oct 23, 2026.

That is below its ten-year median of 3.0×, lower than on 82% of days in the last ten years.

Over that time it ranged from 0.4× in Mar 2023 to 199× in Mar 2018.

The median for 10 large drugmakers of a similar size is 2.4×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far1.4×1.4×29.3×
202510.6×1.7×23.3×
20243.6×0.6×5.3×
20230.7×0.4×1.4×
20221.0×1.0×2.9×
20213.1×2.5×3.9×
20202.6×2.1×3.3×
20192.5×1.9×4.5×
20183.3×3.0×199×
2017112×25.6×112×
201638.5×38.5×50.4×
201557.6×18.9×58.3×
201441.4×36.3×45.3×
201325.7×9.4×27.2×
20128.6×2.8×9.8×
20112.8×2.1×4.2×

Against its peers

Companies in Drug Manufacturers - General nearest Nektar Therapeutics' size, closest first, today.

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Nektar Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.